| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Division of Endocrinology and Metabolism (Y.H., D.Y., I.M., M.K., J.K., M.S., K.N.), Department of Medicine, Kurume University School of Medicine, Fukuoka, 830 Japan; and Eye Division of Olympia Clinic (Y.I.), 150 Tokyo, Japan
Address all correspondence and requests for reprints to: Dr. Yuji Hiromatsu, Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830 Japan.
We used flow cytometry to investigate the effects of nicotinamide, an
inhibitor of poly (ADP ribose) synthetase, on the cell-surface
expression of cytokine-induced human leukocyte antigen (HLA)-A,B,C
antigen, HLA-DR antigen, intercellular adhesion molecule 1, CD44, and
Fas expression in cultured orbital fibroblasts from patients with
thyroid-associated ophthalmopathy. After two to seven passages,
cultured orbital fibroblasts were incubated for 3 days with interferon
or tumor necrosis factor
in the presence of nicotinamide.
Nicotinamide inhibited the induction of both HLA-DR and
intercellular adhesion molecule 1 expression by cytokines on
fibroblasts but did not interfere with induction of HLA-A,B,C, or CD44
expression. Nicotinamide also inhibited the proliferation of
orbital fibroblasts, as assessed by a [3H]-thymidine
incorporation assay and cell counts. Nicotinamide also enhanced the
expression of the apoptosis-mediating protein Fas on fibroblasts. Our
data suggest that nicotinamide inhibits cytokine-induced activation of
fibroblasts and thus may decrease the autoimmune injury to the orbit in
thyroid-associated ophthalmopathy.
This article has been cited by other articles:
![]() |
C.-C. Tsai, S.-C. Kao, C.-Y. Cheng, H.-C. Kau, W.-M. Hsu, C.-F. Lee, and Y.-H. Wei Oxidative Stress Change by Systemic Corticosteroid Treatment Among Patients Having Active Graves Ophthalmopathy Arch Ophthalmol, December 1, 2007; 125(12): 1652 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Wiersinga and M. F. Prummel Pathogenesis of Graves' Ophthalmopathy--Current Understanding J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 501 - 503. [Full Text] |
||||
![]() |
L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |